Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

Summary

Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.

Conditions

• Parkinson Disease

Interventions

DRUG

Levodopa

Participants will take levodopa in dosages prescribed by their care provider. Patients will be instructed to not take their regularly prescribed PD medications for 12 hours prior to the study assessment, as is typical for clinical evaluations in patients with PD. Participants will be tested in both levodopa-off (after 12 hours of not having medication) and levodopa-on states.

DEVICE

Clinical DBS Setting

Deep brain stimulation performed with the patients' optimized clinical setting.

DEVICE

Sham DBS

Deep brain stimulation performed with sham stimulation.

DEVICE

DBS Setting Maximizing Prefrontal Activation

Deep brain stimulation performed to maximize the activation of the prefrontal cortico-STN projections.

DEVICE

DBS Setting Minimizing Prefrontal Activation

Deep brain stimulation performed to minimize the activation of the prefrontal cortico-STN projections.

Sponsors & Collaborators

• National Institute of Neurological Disorders and Stroke (NINDS)

  collaborator NIH

• Emory University

  lead OTHER

Principal Investigators

• Svjetlana Miocinovic, MD, PhD · Emory University

Study Design

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

45 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-08-09

Primary Completion

2026-07-31

Completion

2026-07-31

FDA Drug

Yes

FDA Device

Yes

Countries

• United States

Study Locations